Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of gonadorelin peptide in China. Welcome to wholesale bulk high quality gonadorelin peptide for sale here from our factory. Good service and reasonable price are available.
Gonadorelin peptide is a ten-peptide hormone naturally synthesized by the hypothalamus. As a key messenger in the human endocrine system, its main function is to stimulate the anterior pituitary gland to release two important gonadotropins: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This mechanism makes it the core for regulating gonadal function, directly influencing the steroid hormone production of the testes and ovaries, gamete formation, and overall reproductive health. In the clinical field, the synthetic version of it is used for diagnosis. By evaluating the pituitary function, it helps to identify whether the cause of hypogonadism lies in the hypothalamus or the pituitary itself.
Our products Form
Gonadorelin COA
Core Drugs for Reproductive System Diseases Treatment
In male patients suffering from infertility associated with hypothalamic-pituitary-testicular (HPT) axis dysfunction, gonadorelin peptide serves as a key therapeutic agent by restoring the normal regulatory function of this critical endocrine axis. As a synthetic analog of endogenous gonadotropin-releasing hormone (LHRH), it mimics the natural pulsed release pattern of LHRH from the hypothalamus, which is essential to avoid pituitary desensitization and ensure the sustained secretion of pituitary gonadotropins.
By activating the HPT axis, gonadorelin effectively stimulates the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH): LH promotes the production of testosterone in testicular Leydig cells, while FSH enhances spermatogenesis in the seminiferous tubules, thereby comprehensively increasing testosterone levels and improving sperm production, motility, and overall quality.This therapeutic effect is particularly beneficial in specific subgroups of male infertility patients.
For children diagnosed with cryptorchidism-an condition where one or both testicles fail to descend into the scrotum spontaneously-short-term pulsed administration of gonadorelin during the critical developmental period (usually before 1 year of age) can effectively stimulate testicular descent.
This non-surgical intervention not only avoids the physical trauma and potential complications of surgical orchidopexy but also helps preserve long-term testicular function, reducing the risk of infertility or testicular malignancy in adulthood.
For adult patients with idiopathic oligospermia-a common cause of male infertility characterized by abnormally low sperm concentration with no clear underlying etiology (such as infection, obstruction, or genetic abnormalities)-continuous pulsed gonadorelin therapy over 3 to 6 months can significantly improve sperm parameters. Clinical data consistently show that this therapy can increase sperm concentration by 40%-50% compared with baseline, and the subsequent natural conception rate is also notably improved, offering a safe and effective alternative to more invasive treatment options.
Breakthrough Progress in Hormone-dependent Tumor Treatment
Endocrine regulation is a cornerstone of adjuvant therapy for estrogen receptor-positive (ER-positive) breast cancer, as tumor growth in these patients is closely dependent on estrogen stimulation. Gonadorelin, a synthetic analog of gonadotropin-releasing hormone (LHRH), plays a vital role in this therapeutic strategy by targeting the hypothalamic-pituitary-ovarian axis to inhibit ovarian function. Unlike traditional surgical oophorectomy, gonadorelin exerts its effect through a reversible mechanism: it initially stimulates the pituitary gland to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH) but then induces pituitary desensitization with continuous administration, ultimately suppressing ovarian estrogen synthesis and secretion.
This reduction in circulating estrogen levels deprives ER-positive breast cancer cells of the key growth factor they rely on, thereby inhibiting tumor progression and significantly lowering the risk of local recurrence and distant metastasis.In clinical practice, gonadorelin peptide is rarely used as a monotherapy; instead, it is commonly combined with other endocrine agents to enhance therapeutic efficacy. When administered in conjunction with tamoxifen (a selective estrogen receptor modulator) or aromatase inhibitors (which block peripheral estrogen synthesis), it creates a synergistic effect that further suppresses estrogen signaling in tumor cells.
Clinical trials and long-term follow-up data have confirmed that this combined therapy can increase the 5-year disease-free survival rate by 15%-20% in ER-positive breast cancer patients, especially in premenopausal women with high-risk features such as lymph node involvement or large tumor size.A notable advantage of gonadorelin over irreversible ovarian ablation (such as surgical removal of the ovaries) is its reversible inhibitory characteristic. For young premenopausal patients with ER-positive breast cancer who wish to retain their reproductive potential after completing adjuvant therapy, discontinuing gonadorelin can allow ovarian function to gradually recover.
This feature addresses a critical unmet need in young breast cancer survivors, offering them the possibility of conceiving naturally or through assisted reproductive technologies in the future, while still ensuring effective tumor control during treatment. Additionally, compared to surgical oophorectomy, gonadorelin avoids the surgical trauma, postoperative complications, and sudden onset of menopause-related symptoms (such as hot flashes, mood swings, and osteoporosis), improving patients' quality of life during and after therapy .
Therapeutic Advantages
Gonadorelin mimics the natural pulsatile release of LHRH, avoiding the side effects of traditional chemical messenger replacement therapy (such as osteoporosis, metabolic disorders). Its reversible inhibitory characteristic provides the possibility for young patients to retain their reproductive function.
In addition to intravenous injection, the development of nasal sprays and sustained-release microsphere preparations has significantly improved patient compliance. For example, the bioavailability of nasal administration reaches 30%, and it can avoid injection site pain and thrombophlebitis.
Basic research shows that LHRH receptors are expressed on the surface of tumor cells such as breast cancer and ovarian cancer, providing new ideas for targeted therapy. In addition, its potential roles in neuroprotection (such as Alzheimer's disease) and metabolic regulation (such as obesity-related hypogonadism) are also being explored.
Mechanism of Action
Molecular Targets and Basis of Receptor Binding
Gonadorelin peptide is a synthetic decapeptide of gonadotropin-releasing hormone (LHRH). Endogenous LHRH is synthesized by neuroendocrine cells in the arcuate nucleus of the hypothalamus. Gonadorelin shares an identical amino acid sequence with natural LHRH and specifically targets LHRH receptors (GnRHRs) located on the membrane surface of pituitary gonadotropic cells.
As a member of the G protein-coupled receptor (GPCR) superfamily, GnRHR features a specific binding pocket within its extracellular domain.
Key amino acid residues at the N-terminus and C-terminus of the product precisely intercalate with hydrophobic and charged sites on the receptor to form a stable ligand-receptor complex. In its unbound state, GnRHR exhibits no signal transduction activity. Upon binding with gonadorelin, the receptor undergoes conformational rearrangement to expose intracellular G protein binding sites and initiate downstream signaling cascades. It shows no cross-binding to receptors related to growth hormone or prolactin, granting extremely high target specificity.
Activation of Intracellular Signaling Pathways in Pituitary Cells
Receptor conformational changes trigger coupling with Gq-type G proteins, which in turn activate phospholipase C (PLC). PLC catalyzes the hydrolysis of membrane phosphatidylinositol bisphosphate to generate two secondary messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG).
IP3 diffuses to the endoplasmic reticulum in the cytoplasm, opening calcium channels and triggering massive release of stored calcium ions, resulting in a sharp transient rise in intracellular calcium concentration.
Meanwhile, DAG persistently activates protein kinase C (PKC). Calcium ions and PKC form a synergistic regulatory axis that jointly activates the intracellular transcription factors ERK1/2. After phosphorylation, ERK translocates into the nucleus and binds to the promoter regions of genes encoding luteinizing hormone (LH) and follicle-stimulating hormone (FSH), initiating gene transcription and protein synthesis of both gonadotropins. A single pulsatile stimulation with gonadorelin only activates the pathway transiently and does not induce receptor desensitization.
Physiological Effects via Hierarchical Regulation of the Gonadal Axis
LH and FSH synthesized and secreted by the pituitary travel through the bloodstream to target the gonads, accomplishing hierarchical regulation of the hypothalamic-pituitary-gonadal (HPG) axis.In female organisms, FSH acts on ovarian granulosa cells to facilitate follicular proliferation and development, as well as estrogen synthesis.
A surge in LH triggers follicle maturation and ovulation, while stimulating corpus luteum formation and progesterone secretion. In male organisms, FSH activates testicular Sertoli cells to promote early spermatogenic development; LH binds to testicular Leydig cells to drive testosterone synthesis and secretion.
Pulsatile administration of gonadorelin sustains a stable rhythm of gonadotropin secretion, restores normal endocrine function of the gonads, balances androgen and estrogen levels, and rectifies disrupted reproductive endocrine rhythms.
Negative Feedback Mechanism of Receptor Desensitization Under Long-Term Continuous Administration
Continuous high-concentration infusion of the peptide leads to prolonged occupancy of LHRH receptors by ligands, triggering receptor internalization and ubiquitination-mediated degradation. This drastically reduces the number of functional GnRHRs on pituitary cell membranes, an effect known as receptor desensitization.
Loss of functional receptors blocks downstream calcium signaling and the ERK pathway, markedly suppressing the synthesis and release of LH and FSH, accompanied by an abrupt plummet in gonadal chemical messenger secretion, resulting in pharmacologically induced gonadal suppression. This bidirectional mechanism underpins the differentiated clinical applications of gonadorelin: low-dose pulsatile dosing activates the gonadal axis, whereas continuous high-dose dosing suppresses gonadal function, matching two diametrically opposite clinical demands-reproductive regulation and treatment of chemical messenger-dependent disorders.
Co-regulatory Pathway Mediated by Endogenous Hormone Negative Feedback
Estrogens and androgens secreted by the gonads circulate back to exert inhibitory effects on the hypothalamus and pituitary, forming a closed negative feedback loop. Low sex hormone levels elevate the excitability of hypothalamic LHRH neurons and amplify signal output from gonadorelin-like peptides; conversely, high sex hormone levels inhibit hypothalamic LHRH release and reduce pituitary responsiveness to gonadorelin.
The product bypasses the restraints of endogenous hormone negative feedback to directly stimulate the pituitary and reverse HPG axis imbalance, enabling differential diagnosis of lesions localized to the hypothalamus, pituitary or gonads. After desensitizing administration, the resultant low sex hormone levels alleviate chemical messenger-driven tissue proliferation to achieve therapeutic intervention for relevant diseases.
Gonadorelin peptide is an artificially synthesized ten-peptide analogue of gonadotropin-releasing hormone (LHRH). Its development prospects have demonstrated significant potential in various fields such as reproductive medicine, cancer treatment, chronic disease management, and scientific innovation.
Diversified Expansion of Clinical Application Scenarios
Main drugs in the field of reproductive health
The core function of gonadorelin is to stimulate the pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), thereby regulating the secretion of sex hormones. Currently, its clinical applications have covered scenarios such as infertility treatment, cryptorchidism correction, and diagnosis of amenorrhea. For example, in male infertility, pulse administration can simulate the physiological release of LHRH, restoring the function of the hypothalamus-pituitary-testis axis; in the diagnosis of female amenorrhea, by detecting the peak changes of LH/FSH after administration, it can precisely distinguish the causes of hypothalamic or pituitary origin.
In the future, with the deepening understanding of reproductive endocrine mechanisms, its indications are expected to expand to complex diseases such as polycystic ovary syndrome and premature ovarian failure.
New Choice for Chronic Endocrine Disease Management
For gonadal dysfunction caused by hypothalamic or pituitary damage, traditional chemical messenger replacement therapy has side effects such as osteoporosis and metabolic disorders, while gonadorelin, through physiological regulation of chemical messenger secretion, can reduce the risk of long-term medication.
For example, in patients after pituitary tumor surgery, continuous low-dose administration can maintain gonadal function and avoid sudden discontinuation of medication causing hormonal fluctuations. Additionally, its efficacy in special types of endocrine diseases such as precocious menopause and galactorrhea amenorrhea is also being explored.
Breakthrough Progress in Cancer Treatment
Targeted Inhibition of Hormone-dependent Tumors
The product and its analogues inhibit LH secretion by down-regulating LHRH receptor sensitivity, thereby reducing testosterone/estrogen levels and blocking the growth signals of chemical messenger-dependent tumors (such as prostate cancer, breast cancer). Animal experiments show that continuous exposure to it can reduce the risk of breast cancer cell proliferation by 70% and increase the apoptosis rate of prostate cancer cells by 40%. Currently, LHRH agonists (such as leuprorelin) are widely used in clinical practice, while gonadorelin, as a natural LHRH analogue, has a shorter half-life (about 6 minutes) and a lower risk of receptor desensitization. In the future, through modified formulations (such as sustained-release microspheres), it may achieve more precise chemical messenger regulation.
Synergistic Enhancement of Tumor Immunotherapy
Recent studies have found that LHRH receptors are expressed on the surface of various tumor cells, providing new ideas for targeted therapy. For example, fusing LHRH with ribonuclease (hpRNase1) can construct an enzyme-peptide complex specifically killing tumor cells. Additionally, it can enhance the efficacy of PD-1/PD-L1 inhibitors by regulating the immune microenvironment (such as inhibiting the function of regulatory T cells), providing theoretical support for combined immunotherapy.
Integration of Personalized Medicine and Precise Drug Administration
Gene Testing Guided Individualized Treatment
With the development of genomics, the association between LHRH receptor gene polymorphisms (such as rs10872677) and differences in drug responses has gradually become clear. For example, patients carrying specific genotypes have a higher sensitivity to LHRH pulse therapy and can achieve maximum efficacy by adjusting the administration frequency. In the future, combined with dynamic monitoring of hormone levels (such as AMH, inhibin B) and gene testing, a personalized medication model for gonadorelin peptide can be constructed.
Research and Development of New Delivery Systems
To overcome the limitation of its short half-life, new formulations such as nanocarriers and transdermal patches are under development. For example, poly(lactic-co-glycolic acid) (PLGA) microspheres can achieve sustained-release of the drug for 28 days, significantly improving patient compliance; nasal spray through mucosal absorption bypasses the first-pass effect, increasing the bioavailability to over 30%. These innovations will drive it to transform from a "therapeutic drug" to a "chronic disease management tool".
Driving Scientific Research Innovation and Interdisciplinary Collaboration
Basic Research Reveals New Mechanisms
Epigenetic studies indicate that it can influence germ cell development by regulating DNA methylation. For example, in a cryptorchidism model, the drug reverses hypermethylation in the promoter region of tumor suppressor genes, restoring testicular descent function. Additionally, its potential roles in neuroprotection (e.g., Alzheimer's disease) and metabolic regulation (e.g., obesity-related hypogonadism) are currently under investigation.
Interdisciplinary Technologies Enable Product Upgrades
The application of artificial intelligence in drug design has accelerated the development of it analogues. For example, by predicting peptide chain conformations using deep learning models, mutated variants with fivefold enhanced activity (such as [D-Trp6]-GnRH) have been successfully designed. Meanwhile, 3D bioprinting technology can construct in vitro models of the hypothalamic-pituitary-gonadal axis, providing an efficient platform for drug screening.
1. High-Performance Liquid Chromatography (HPLC): Core Purity and Stability Analysis
HPLC is the most commonly used method for gonadorelin analysis, mainly applied for purity detection and stability evaluation. Reversed-phase HPLC is preferred, using a C18 chromatographic column with gradient elution to separate gonadorelin from impurities and degradation products. It can accurately determine the purity of synthetic gonadorelin (requiring ≥95% purity) and monitor its degradation kinetics in aqueous solutions, with photodiode array detection ensuring detection accuracy. This method is also specified in pharmacopeias for identifying gonadorelin by comparing the retention time of the sample's major peak with the standard preparation.
2. Mass Spectrometry (MS): Precision Qualification and Metabolite Detection
MS is often combined with HPLC (LC-MS/MS, LC-HRMS) for high-sensitivity analysis. It is mainly used to identify gonadorelin's chemical structure, detect its metabolites, and quantify trace levels in biological samples. For example, LC-HRMS can quantify gonadorelin in plasma or urine down to the low picogram level, while LC-MS/MS is used to characterize its degradation products with high resolution. This method is crucial for clinical pharmacokinetic research and anti-doping detection.
3. Immunoassay: Rapid Quantitative Detection
Immunoassay methods, including chemiluminescence immunoassay (CLIA) and biomimetic enzyme-linked immunosorbent assay (BELISA), are used for rapid quantitative analysis of gonadorelin in biological samples. CLIA has high sensitivity (detection limit 0.1pg/mL) for serum/plasma samples, while BELISA uses molecularly imprinted polymers to achieve rapid quantification with good reproducibility. These methods are suitable for large-scale clinical sample detection and anti-doping screening due to their simplicity and high efficiency.
FAQ
What is gonadorelin peptide used for?
+
-
Gonadorelin is used to test how well the hypothalamus and the pituitary glands are working. It is also used to cause ovulation (release of an egg from the ovary) in women who do not have regular ovulation and menstrual periods because the hypothalamus gland does not release enough GnRH.
What are the side effects of gonadorelin injections?
+
-
Headache, nausea, and mild abdominal pain may occur with menstrual bleeding. Injection site reactions (such as mild irritation, redness, bruising) may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.
Does gonadorelin build muscle?
+
-
Increased Testosterone Levels: Gonadorelin stimulates the production of testosterone, which can improve energy levels, strength, and overall vitality. Enhanced Muscle Mass: Higher testosterone levels support muscle growth and maintenance, contributing to a more toned and defined physique.
Hot Tags: gonadorelin peptide, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Best Growth Hormone Releasing Peptide CAS 87616 84 0, DecaPeptide 12 CAS 137665 91 9, Epitalon Powder CAS 307297 39 8, GLP 1 Peptide CAS 87805 34 3, sermorelin powder, Bremelanotide Powder CAS 189691 06 3